Physician profile
Yize Wang
NPI 1053576207
$7,116.15
in general payments reported to CMS, 2019-2025
34 companies · $2,282 in 2025
The $2,282 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $413 · 2021: $618 · 2022: $543 · 2023: $1,241 · 2024: $1,844 · 2025: $2,282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,323 · Education: $44.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,323.29 |
| Education | $44.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,243.18 | 2019-2025 | Skyrizi, Rinvoq, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $969.95 | 2020-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $782.25 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Intercept Pharmaceuticals, INC. | $470.68 | 2021-2024 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $408.46 | 2019-2025 | Xifaxan, Trulance |
| Celgene Corporation | $389.08 | 2022-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $343.74 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $292.83 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $247.01 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $234.17 | 2024-2025 | Voquezna |
| Allergan, INC. | $200.00 | 2020 | |
| Celltrion USA INC. | $167.64 | 2024-2025 | Vegzelma, Zymfentra |
| Pfizer INC. | $164.96 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $163.07 | 2024-2025 | Zenpep |
| Stryker Corporation | $151.95 | 2023 | Mako |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $136.78 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $102.59 | 2023-2025 | |
| Shionogi INC | $81.36 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $58.20 | 2019-2023 | Dificid |
| Nestle Healthcare Nutrition INC. | $53.90 | 2020-2023 | |
| Amgen INC. | $53.13 | 2023-2025 | Uplizna, Avsola, Amjevita |
| Qol Medical, LLC | $50.25 | 2023-2024 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $46.23 | 2023-2024 | Linzess |
| Ferring Pharmaceuticals INC. | $41.95 | 2022-2023 | Rebyota |
| Organon LLC | $41.85 | 2023 | Renflexis, Hadlima |
| Ardelyx, INC. | $40.54 | 2024-2025 | Ibsrela |
| Ambu INC. | $39.48 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $32.94 | 2024 | Bylvay |
| Fresenius Kabi USA, LLC | $30.36 | 2024 | Idacio |
| Exact Sciences Corporation | $21.75 | 2023 | Cologuard Collection Kit |
| Steris Corporation | $15.63 | 2021 | |
| W. L. Gore & Associates, INC. | $14.58 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $13.28 | 2022 | |
| Redhill Biopharma INC. | $12.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yize Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.